Kenvue appoints 3 new directors, including Starboard's CEO, settles proxy fight

Kenvue Inc.

Board temporarily expands from 11 to 14 directors; to reduce to 13 after 2025 annual meeting.
Starboard withdraws its slate of director nominees and agrees to standstill through mid-2026.
New directors: Sarah Hofstetter (Profitero), Erica Mann (ex-Bayer Consumer Health), and Starboard's Jeffrey Smith.
Hofstetter appointed to Audit Committee; Mann to Nominating, Governance & Sustainability; Smith to Compensation Committee.

item 1.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sarah Hofstetter

Director

KVUE · Kenvue Inc.

Effective: 2025-03-05
Filed: March 5, 2025, 6:59 PM ET

Ms. Hofstetter has been appointed to the Audit Committee of the Board.

Appointed

Erica Mann

Director

KVUE · Kenvue Inc.

Effective: 2025-03-05
Filed: March 5, 2025, 6:59 PM ET

Ms. Mann has been appointed to the Nominating, Governance & Sustainability Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah Hofstetter was appointed as Director at Kenvue Inc..

Action: appointed
Role: Director

Exact text from the filing

Ms. Hofstetter has been appointed to the Audit Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Erica Mann was appointed as Director at Kenvue Inc..

Action: appointed
Role: Director

Exact text from the filing

Ms. Mann has been appointed to the Nominating, Governance & Sustainability Committee of the Board.

View on SEC.gov

Kenvue Inc. filing history →

Source: SEC EDGAR

accession 0001944048-25-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.